FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094778049> ?p ?o ?g. }

• W2094778049 endingPage "30" @default.
• W2094778049 startingPage "24" @default.
• W2094778049 abstract "Failure of anti-TNF treatment in inflammatory bowel disease (IBD) patients can take on several forms, each posing distinct etio-pathogenic considerations and management dilemmas.The aim of this study is to review the mechanisms responsible for the various forms of anti-TNF failures in IBD and to elucidate strategies for optimizing clinical efficacy.Primary failures of anti-TNF induction therapy occur in up to 40% of patients in clinical trials and in 10-20% in clinical series. Longer disease duration, smoking and several genetic mutations are predisposing factors for primary failures. Curiously, primary non-response is probably not a class-effect phenomenon since switching to another anti-TNF is effective in over 50% of such patients. Secondary loss of response is also a common clinical problem with incidence ranging between 23 and 46% at 12months after anti-TNF initiation. Underlying mechanisms are often related to increased anti-TNF clearance by anti-drug antibodies, but may also include other causes for recalcitrant IBD activity as well as disorders that are unrelated to IBD itself. Astute management begins with verifying the presence of uncontrolled inflammatory IBD activity as a cause for patient's symptoms. Next, it is prudent to consider a trial of wait-and-see approach, since in some patients with mild-moderate symptoms, loss of response may resolve without alteration of therapy. If it does not, measuring anti-TNF trough levels and anti-drug antibodies may clarify the underlying mechanism in individual patients although there are still limited and conflicting data regarding the role of these measurements in guiding the choice between dose-intensification, switch to another anti-TNF or to another immuno-modulator, and the addition of an immuno-modulator as a combination therapy with the failing anti-TNF. Anti-TNF re-induction after prior drug-holiday is a distinct clinical scenario and scarce evidence suggests re-induction outcome to be dependent on the circumstances when drug-holiday was commenced. Finally, discontinuation of anti-TNF in patients with stable deep clinico-biologic and mucosal remission may be a viable option, as in these carefully selected patients the majority may enjoy long-term remission without the need for continued anti-TNF treatment." @default.
• W2094778049 created "2016-06-24" @default.
• W2094778049 creator A5047907008 @default.
• W2094778049 creator A5062860652 @default.
• W2094778049 creator A5080002704 @default.
• W2094778049 date "2014-01-01" @default.
• W2094778049 modified "2023-10-18" @default.
• W2094778049 title "Optimizing anti-TNF treatments in inflammatory bowel disease" @default.
• W2094778049 cites W1965781207 @default.
• W2094778049 cites W1969917809 @default.
• W2094778049 cites W1978593886 @default.
• W2094778049 cites W1981963599 @default.
• W2094778049 cites W1988152800 @default.
• W2094778049 cites W1991810959 @default.
• W2094778049 cites W1994534603 @default.
• W2094778049 cites W1997999969 @default.
• W2094778049 cites W1998966252 @default.
• W2094778049 cites W1998974262 @default.
• W2094778049 cites W2000739170 @default.
• W2094778049 cites W2003904406 @default.
• W2094778049 cites W2020710276 @default.
• W2094778049 cites W2022301990 @default.
• W2094778049 cites W2024218526 @default.
• W2094778049 cites W2026116536 @default.
• W2094778049 cites W2030638161 @default.
• W2094778049 cites W2031860350 @default.
• W2094778049 cites W2036868912 @default.
• W2094778049 cites W2039846899 @default.
• W2094778049 cites W2041750210 @default.
• W2094778049 cites W2050154180 @default.
• W2094778049 cites W2057524655 @default.
• W2094778049 cites W2065795543 @default.
• W2094778049 cites W2072640801 @default.
• W2094778049 cites W2080037503 @default.
• W2094778049 cites W2081071002 @default.
• W2094778049 cites W2088513474 @default.
• W2094778049 cites W2090133088 @default.
• W2094778049 cites W2093504865 @default.
• W2094778049 cites W2094159990 @default.
• W2094778049 cites W2098295867 @default.
• W2094778049 cites W2102265867 @default.
• W2094778049 cites W2102952098 @default.
• W2094778049 cites W2105311242 @default.
• W2094778049 cites W2106010005 @default.
• W2094778049 cites W2111018767 @default.
• W2094778049 cites W2111202604 @default.
• W2094778049 cites W2114095680 @default.
• W2094778049 cites W2117212747 @default.
• W2094778049 cites W2118088660 @default.
• W2094778049 cites W2118559127 @default.
• W2094778049 cites W2121609590 @default.
• W2094778049 cites W2126807394 @default.
• W2094778049 cites W2134803931 @default.
• W2094778049 cites W2142082253 @default.
• W2094778049 cites W2146963207 @default.
• W2094778049 cites W2151736364 @default.
• W2094778049 cites W2152353173 @default.
• W2094778049 cites W2153438195 @default.
• W2094778049 cites W2159143303 @default.
• W2094778049 cites W2166771071 @default.
• W2094778049 cites W2171297959 @default.
• W2094778049 cites W2171341132 @default.
• W2094778049 cites W2177368405 @default.
• W2094778049 cites W2615184173 @default.
• W2094778049 doi "https://doi.org/10.1016/j.autrev.2013.06.002" @default.
• W2094778049 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23792214" @default.
• W2094778049 hasPublicationYear "2014" @default.
• W2094778049 type Work @default.
• W2094778049 sameAs 2094778049 @default.
• W2094778049 citedByCount "301" @default.
• W2094778049 countsByYear W20947780492014 @default.
• W2094778049 countsByYear W20947780492015 @default.
• W2094778049 countsByYear W20947780492016 @default.
• W2094778049 countsByYear W20947780492017 @default.
• W2094778049 countsByYear W20947780492018 @default.
• W2094778049 countsByYear W20947780492019 @default.
• W2094778049 countsByYear W20947780492020 @default.
• W2094778049 countsByYear W20947780492021 @default.
• W2094778049 countsByYear W20947780492022 @default.
• W2094778049 countsByYear W20947780492023 @default.
• W2094778049 crossrefType "journal-article" @default.
• W2094778049 hasAuthorship W2094778049A5047907008 @default.
• W2094778049 hasAuthorship W2094778049A5062860652 @default.
• W2094778049 hasAuthorship W2094778049A5080002704 @default.
• W2094778049 hasConcept C126322002 @default.
• W2094778049 hasConcept C177713679 @default.
• W2094778049 hasConcept C17991360 @default.
• W2094778049 hasConcept C203014093 @default.
• W2094778049 hasConcept C2777138892 @default.
• W2094778049 hasConcept C2778176773 @default.
• W2094778049 hasConcept C2778260677 @default.
• W2094778049 hasConcept C2779134260 @default.
• W2094778049 hasConcept C2779280984 @default.
• W2094778049 hasConcept C2780035454 @default.
• W2094778049 hasConcept C535046627 @default.
• W2094778049 hasConcept C71924100 @default.
• W2094778049 hasConcept C98274493 @default.
• W2094778049 hasConceptScore W2094778049C126322002 @default.

• next